SpringWorks Therapeutics Inc

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

SpringWorks reports robust Q1 revenue, poised for patient-centric growth

SpringWorks Therapeutics demonstrated strong financial performance and market acceptance for OGSIVEO in Q1 2024.
The company's focus on patient-centric care and pipeline advancement positions them well for future growth and innovation.
While facing challenges in market competition and regulatory landscape, SpringWorks has opportunities for expansion and diversification.

SpringWorks reports robust Q2 earnings, focuses on expanding treatments

SpringWorks Therapeutics delivered strong financial performance in Q2 2024, driven by $40.2 million in net product revenue for OGSIVEO.
The company's focus on expanding OGSIVEO reach, advancing mirdametinib, and developing its emerging portfolio underscores its commitment to innovation.
While facing challenges such as rising operating expenses, SpringWorks remains well-positioned with a healthy cash reserve to pursue growth opportunities.
Strategically navigating challenges and capitalizing on opportunities will be crucial for SpringWorks to sustain its momentum and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 –

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

– PDUFA Action Date Set for August 27, 2023 – – PDUFA Action Date Set for August 27, 2023 –

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, will present today at the 41st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), and a live webcast will be available at ir.springworkstx.com. Ahead of the presentation, the Company highlighted its 2022 accomplishments and announced its anticipated key milestones for 2023.

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) on behalf of the company's long-term investors.The investigation seeks to determine whether SpringWorks has issued false and misleading statements and/or failed to disclose material facts to its investors, thereby violating the securities laws and causing harm to the company's shareholders.SpringWorks shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.

Kaskela Law LLC Announces Investigation of SpringWorks Therapeutics, Inc. (SWTX) and Encourages Long-Term SWTX Investors to Contact the Firm

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET.

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 –

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

CONCORD, Mass. , Nov. 1, 2022 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, for the development of a systems pharmacology model in multiple myeloma.

Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma

The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 211.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet

STAMFORD, Conn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 2 trial evaluating nirogacestat, SpringWorks' investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors.

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

Strengthens Financial Position to Over $600 Million in Cash, Cash Equivalents and Marketable Securities, Upon Closing of the Financing Strengthens Financial Position to Over $600 Million in Cash, Cash Equivalents and Marketable Securities, Upon Closing of the Financing

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments -

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

– Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints –

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET.

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global commercial strategy and operations.

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of SpringWorks Therapeutics, Inc. ("Springworks" or "the Company") (NASDAQ: SWTX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in SpringWorks Therapeutics, Inc. with Losses to Contact the Firm

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80%.

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch

-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 -- -- New Phase 2 Study Announced to Evaluate Nirogacestat in Patients with Ovarian Granulosa Cell Tumors --

SpringWorks Therapeutics to Present Progress Across the Company's Targeted Oncology Portfolio at Virtual R&D Day

STAMFORD, Conn., June 09, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15th at 8:40 a.m. PT / 11:40 a.m. ET.

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rare diseases announced encouraging results from its DeFi study. The trial was a placebo-controlled, double-blind third phase study assessing the safety, tolerability, and efficacy of the company's experimental oral gamma-secretase inhibitor, Nirogacestat, in the treatment of […] The post Here is why SpringWorks Therapeutics jumped 20% appeared first on Invezz.

Here is why SpringWorks Therapeutics jumped 20%

Arcellx

Iovance Biotherapeutics

Mirati Therapeutics

Zymeworks Inc

The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week's American Society of Clinical Oncology annual meeting.

Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma -

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

News for SpringWorks Therapeutics Inc Stock (SWTX)